Daewoong Pharmaceutical

M8 Pharmaceuticals and Daewoong Pharmaceutical strengthen their strategic partnership by signing an exclusive licensing agreement for Envlo™ (Enavoglifozin) for Brazil and Mexico

Retrieved on: 
Tuesday, February 28, 2023
Blood pressure, Diabetes, Safety, Latin, Metformin, Partnership, SGLT2, Daewoong Pharmaceutical, Patient, Inhibitor, Glycated hemoglobin, MEXICO, E-64, Pharmaceutical industry, IQVIA

MEXICO CITY, Feb. 28, 2023 /PRNewswire/ -- M8 Pharmaceuticals and Daewoong Pharmaceuticals announced they have signed an exclusive licensing agreement whereby M8 will have the rights to register and commercialize Envlo™ (Enavoglifozin) for Brazil and Mexico.

Key Points: 
  • MEXICO CITY, Feb. 28, 2023 /PRNewswire/ -- M8 Pharmaceuticals and Daewoong Pharmaceuticals announced they have signed an exclusive licensing agreement whereby M8 will have the rights to register and commercialize Envlo™ (Enavoglifozin) for Brazil and Mexico.
  • Phase 3 clinical trials have been performed on type 2 diabetes patients and its results demonstrated excellent effects in dropping blood sugar level drop.
  • The HbA1c decreased in the Enavogliflozin group by approximately 1% over the placebo group, which was statistically significant.
  • M8 Pharmaceuticals continues its commitment of bringing proven and innovative products to Latin American patients, and the agreement reinforces its commitment and capabilities in the area of cardiometabolism.

Evolus Not Affected by Recent Korean Court Ruling

Retrieved on: 
Friday, February 10, 2023
Cosmetics, Retail, Health, Luxury, Consumer, Women, General Health, Generic drug, Daewoong Pharmaceutical

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, issued the following statement.

Key Points: 
  • Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, issued the following statement.
  • Earlier today, the Seoul Central District Court ruled in favor of Medytox, Inc. related to a long-standing trade secret dispute between Medytox and Daewoong Pharmaceutical Co. Ltd.
  • The recent ruling by the Seoul Central District Court does not affect Evolus’ ability to have Jeuveau® or Nuceiva® manufactured and exported by Daewoong or to sell the products in any of its markets.
  • The rights granted to Evolus under the settlement include the right to have Jeuveau® and Nuceiva® manufactured and exported by Daewoong to Evolus and for Evolus to continue to commercialize the product.

AEON Biopharma Confirms Development Strategy and Timelines for ABP-450 Unaffected by Korean Court Ruling on Dispute Between Medytox and Daewoong Pharmaceutical

Retrieved on: 
Saturday, February 11, 2023
AEON, AB toxin, Daewoong Pharmaceutical, Pharmaceutical industry

The settlement contemplates that any Korean litigation between Medytox and Daewoong would not affect the supply of ABP-450 to AEON.

Key Points: 
  • The settlement contemplates that any Korean litigation between Medytox and Daewoong would not affect the supply of ABP-450 to AEON.
  • The rights granted to AEON under the settlement include having ABP-450 manufactured and exported by Daewoong to AEON, and for AEON to continue its planned clinical development and, if approved by government regulators, commercialization of ABP-450.
  • AEON is developing ABP-450 as a treatment for debilitating medical conditions, with an initial focus on the neurosciences market.
  • “As previously announced, we have settled all litigation between AEON and Medytox, and we have a licensing agreement with Daewoong for ABP-450.

Daewoong enters exclusive licensing agreement with CS Pharmaceuticals for Bersiporocin in Idiopathic Pulmonary Fibrosis in the Greater China Region

Retrieved on: 
Tuesday, January 31, 2023
Survival rate, Idiopathic pulmonary fibrosis, PRS, Idiopathic disease, Ophthalmology, IPF, Diagnosis, FastTrack, Development, US, Patient, CSP, Agent handling, Pharmaceutical industry, Pirfenidone, Daewoong Pharmaceutical

Under the terms of the agreement, Daewoong will grant CSP exclusive development and commercialization rights to Bersiporocin in IPF and other respiratory indications.

Key Points: 
  • Under the terms of the agreement, Daewoong will grant CSP exclusive development and commercialization rights to Bersiporocin in IPF and other respiratory indications.
  • Bersiporocin is a first-in-class antifibrotic agent that is being developed by Daewoong.
  • The team has an impressive track record of success in China, providing partners with significant experience in this fast-growing market.
  • Idiopathic Pulmonary Fibrosis is a rare, progressive lung disease in which thickening and hardening of lung tissues cause decline of lung function.

Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates

Retrieved on: 
Wednesday, January 4, 2023
Cancer, Organic acid, LNP, Amine, Daewoong Pharmaceutical, Pharmacokinetics, RNA transfection, Research, PEG, Patient, KRX, Therapy, Quality of life, RNA, Lipid, Vaccine, Pharmaceutical industry

Research collaboration leverages Oncorus’ proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong’s mRNA expertise

Key Points: 
  • Research collaboration leverages Oncorus’ proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong’s mRNA expertise
    ANDOVER, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, and Daewoong Pharmaceutical Co., Ltd. (KRX: 069620), a leading South Korean pharmaceutical company, today announced a research collaboration for the discovery and development of novel lipid nanoparticle (LNP) formulations for mRNA drug candidates.
  • Under the terms of the collaboration, Oncorus and Daewoong will conduct joint research to identify and evaluate formulations of Daewoong’s mRNAs encapsulated in Oncorus’ proprietary LNPs.
  • Oncorus will develop formulated drug candidates at its state-of-the-art manufacturing facility in Andover, Massachusetts.
  • In multiple preclinical models involving repeat intravenous (IV) dosing, Oncorus’ formulations have demonstrated improved tolerability, an enhanced therapeutic window and consistent pharmacokinetics compared to approved formulations.

Daewoong Pharmaceutical announces success in developing a new antidiabetic medication and its aims to enter the market in over 50 countries by 2030

Retrieved on: 
Tuesday, December 6, 2022
Ministry of Food and Drug Safety, Patient, Sale, Ministry, Roy Taylor (scientist), Drug development, Daewoong Pharmaceutical, Quality of life, Multimedia, Metformin, Safety, SGLT2, Pharmaceutical industry, Food, Gemigliptin

Until now, the development and approval of SGLT2 inhibitors have been carried out mainly by multinational pharmaceutical companies.

Key Points: 
  • Until now, the development and approval of SGLT2 inhibitors have been carried out mainly by multinational pharmaceutical companies.
  • Daewoong Pharmaceutical, South Korea's leading healthcare company, became the first domestically to succeed in developing a new antidiabetic drug in this class by obtaining a product license.
  • Daewoong Pharmaceutical plans to actively pursue the global market through this product.
  • At the same time, the company has developed a roadmap to enter the global market over 10 countries including China, Brazil and Saudi Arabia by 2025 and 50 countries by 2030.

Daewoong Pharmaceutical announces success in developing a new antidiabetic medication and its aims to enter the market in over 50 countries by 2030

Retrieved on: 
Tuesday, December 6, 2022
Ministry of Food and Drug Safety, Patient, Sale, Ministry, Roy Taylor (scientist), Drug development, Daewoong Pharmaceutical, Quality of life, Metformin, Safety, SGLT2, Pharmaceutical industry, Food, Gemigliptin

Until now, the development and approval of SGLT2 inhibitors have been carried out mainly by multinational pharmaceutical companies.

Key Points: 
  • Until now, the development and approval of SGLT2 inhibitors have been carried out mainly by multinational pharmaceutical companies.
  • Daewoong Pharmaceutical, South Korea's leading healthcare company, became the first domestically to succeed in developing a new antidiabetic drug in this class by obtaining a product license.
  • Daewoong Pharmaceutical plans to actively pursue the global market through this product.
  • At the same time, the company has developed a roadmap to enter the global market over 10 countries including China, Brazil and Saudi Arabia by 2025 and 50 countries by 2030.

Evolus Broadens Its International Presence with Nuceiva® Launch in Great Britain

Retrieved on: 
Tuesday, October 4, 2022
Women, Biotechnology, Pharmaceutical, Health, Consumer, Luxury, Clinical Trials, Retail, NASDAQ, Medicine, Pharmacy, SEC, General manager, Nasdaq, Private Securities Litigation Reform Act, CEO, COVID-19, Annual report, Botulinum toxin, Health care, U.S. Securities and Exchange Commission, Safety, Efficiency, Security (finance), Patient, Beauty, Allergan, Inc., Pharmaceutical industry, Daewoong Pharmaceutical

The Evolus Innovator and Evolus Early Adopter education programs for healthcare professionals are underway, and interest is high as customers gain their first experiences of using Nuceiva.

Key Points: 
  • The Evolus Innovator and Evolus Early Adopter education programs for healthcare professionals are underway, and interest is high as customers gain their first experiences of using Nuceiva.
  • In the UK, Evolus is partnering with Wigmore Medical, known as a leading supplier of specialist products to aesthetics practitioners.
  • Evolus plans to introduce Nuceiva next in Germany and Austria in the first half of 2023, and is working closely with its partner, Novvia Pharm.
  • During 2023, the company expects to enter additional European countries, and, subject to regulatory approval, will also launch Nuceiva in Australia.

Orthofix Medical and CGBio Announce Strategic Partnership Agreement for Novosis rhBMP-2 Bone Graft Solutions

Retrieved on: 
Tuesday, August 2, 2022
Other Health, Research, General Health, Medical Devices, Other Manufacturing, Clinical Trials, Science, Biotechnology, FDA, Manufacturing, Other Science, Health, Association, Surgeon, Allotransplantation, Database, University, Insurance, USC, Â, Hospital, SEC, Trauma, Public sector banks in India, Solution, Risk, Securities Act of 1933, Securities Exchange Act of 1934, Partnership, American Association, Multimedia, NASDAQ, Quality of life, Achievement, Spine, Clinical trial, Technology, Company, Patient, Orthopedic surgery, Annual report, Terminology, AATB, Drug Quality and Security Act, Communication, Accreditation, American Association of Tissue Banks, Medical device, Pharmaceutical industry, Daewoong Pharmaceutical, Neurosurgery

(NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced a strategic partnership agreement with CGBio, a developer of innovative, synthetic bone grafts currently used clinically in Asia for spine, orthopedic, trauma and dental applications.

Key Points: 
  • (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced a strategic partnership agreement with CGBio, a developer of innovative, synthetic bone grafts currently used clinically in Asia for spine, orthopedic, trauma and dental applications.
  • As a consideration of the agreement, CGBio will receive an upfront payment and potential development milestone payments upon achievement of regulatory milestones.
  • This announcement represents the start of an exciting partnership to bring the next evolution of recombinant bone growth factor technology to the market, said Orthofix President and CEO Jon Serbousek.
  • Novosis is a novel composite bone graft material consisting of a synthetic carrier and rhBMP-2.

Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug

Retrieved on: 
Wednesday, July 20, 2022
Pulmonary fibrosis, View, CEO, Fibrosis, Multimedia, Collagen, Saudi Research and Marketing Group, PRS, Disease, FDA, American, Idiopathic pulmonary fibrosis, Growth, Degenerative disease, Pharmaceutical industry, Research, Daewoong Pharmaceutical

Daewoong Pharmaceutical (CEO Seng-Ho Jeon/Chang-Jae Lee) announced on the 19th that DWN12088, its new treatment for idiopathic pulmonary fibrosis currently under development, has been selected by the FDA for its rapid drug screening process (fast-track).

Key Points: 
  • Daewoong Pharmaceutical (CEO Seng-Ho Jeon/Chang-Jae Lee) announced on the 19th that DWN12088, its new treatment for idiopathic pulmonary fibrosis currently under development, has been selected by the FDA for its rapid drug screening process (fast-track).
  • Accelerated approval and priority review can also be requested once the second phase is complete, meaning Daewoong's idiopathic pulmonary fibrosis treatment DWN12088 will likely be developed more quickly.
  • DWN12088 received idiopathic pulmonary fibrosis Phase 2 IND approval from the FDA last June and was designated an orphan drug in 2019.
  • Daewoong CEO Seng-Ho Jeon commented, "Idiopathic pulmonary fibrosis is a disease with high unmet medical needs despite the existence of treatments.